ArticlePediatric rheumatology online journal2026
Serum and urinary soluble CD163 in children with active lupus nephritis.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLupus nephritis (LN) is a major contributor to morbidity and death in systemic lupus erythematosus (SLE), particularly in children. CD163 is a macrophage- and monocyte-specific receptor that can be cleaved and released as soluble CD163 (sCD163). Both circulating and urinary sCD163 reflect macrophage activation and are elevated in inflammatory and autoimmune conditions, highlighting their potential as biomarkers of renal inflammation. There is unmet need to develop a set of biomarkers that can accurately reflect disease activity and prognosis and differentiate active from non-active cases. In this context, we aimed to evaluate serum and urinary sCD163 levels in children with active LN and to examine their association with established clinical and laboratory markers of SLE activity. Additionally, we explored differences in sCD163 levels between patients with renal versus extrarenal SLE activity and between inflammatory LN and non-inflammatory chronic kidney disease (CKD).
methodsWe enrolled 60 pediatric participants in four qual groups, Group 1: patients with active LN, group 2: SLE non-LN with active extrarenal disease, determined by SLEDAI and BILAG-2004 indices, group 3: non-lupus CKD, and group 4: healthy matched controls. Serum and urine levels of sCD163 were determined in all participants by ELISA.
resultsSerum and urinary sCD163 levels differed significantly among the study groups, with the highest levels in active LN. Patients with active renal BILAG scores A or B had significantly higher sCD163 levels than those with BILAG E, while no significant differences across histopathological classes. Serum sCD163 correlated negatively with eGFR and positively with proteinuria, whereas urinary sCD163 correlated positively with SLEDAI, proteinuria, and prednisolone dose. Both serum and urinary sCD163 distinguished renal from extrarenal SLE activity and LN from non-inflammatory CKD, with complete separation between groups (AUC = 1). No significant correlation was found between serum and urinary sCD163.
conclusionBoth sCD163 levels were associated with LN activity and differed from levels in extrarenal SLE and non-inflammatory CKD, suggesting that sCD163 may serve as a potential biomarker of kidney inflammation in pediatric SLLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.